Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Amplia targets ovarian cancer in new clinical protein inhibitor trial

The PRROSE study will enroll 15 to 20 patients and test whether narmafotinib can improve surgery and chemotherapy outcomes, Amplia said.

Summary by Sydney Morning Herald
Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.

3 Articles

Sydney Morning HeraldSydney Morning Herald
Reposted by
The AgeThe Age
Lean Left

Amplia targets ovarian cancer in new clinical protein inhibitor trial

Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.

·Sydney, Australia
Read Full Article
stocktitan.netstocktitan.net

New ovarian cancer trial targets patients who failed initial chemo

The PRROSE trial plans to enroll 15-20 patients before surgery, testing narmafotinib with carboplatin and paclitaxel to assess safety.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Sydney Morning Herald broke the news in Sydney, Australia on Friday, May 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Business icon

Business

Australia icon

Australia

Australia Economy icon

Australia Economy

Business & Markets icon

Business & Markets

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal